tivantinib + sorafenib

**Tivantinib (ARQ 197) is a selective non-ATP competitive inhibitor of c-MET, a receptor tyrosine kinase implicated in tumor cell proliferation, invasion, and angiogenesis. Sorafenib is a multikinase inhibitor that targets several kinases involved in tumor cell signaling and angiogenesis, including Raf serine/threonine kinases (Raf-1/C-Raf and B-Raf), VEGFRs (vascular endothelial growth factor receptors), PDGFR-β (platelet-derived growth factor receptor beta), KIT, FLT3, and RET. The combination of tivantinib and sorafenib has been investigated for synergistic antitumor effects in various cancers such as hepatocellular carcinoma (HCC), renal cell carcinoma (RCC), melanoma, breast cancer, non-small cell lung cancer (NSCLC), and pancreatic adenocarcinoma. Tivantinib enhances the antitumor effect of sorafenib by decelerating its clearance in HCC cells through inhibition of PXR activation. This combination has shown manageable safety profiles in early-phase clinical trials with some dose-limiting toxicities observed at higher doses.**

Brand names

Nexavar

Other names

ARQ 197 + sorafenibtivantinib + sorafenib